HISTORY
-
- 12.15 Incorporated (KRW 600 million in capital)
-
- 01.29 Raised KRW 410 million through Paid-in Capital Increase
07 KRW 13 billion investment from Ildong Pharmaceutical
07 Incorporated as a subsidiary of Ildong Pharmaceutical
07 ~ 09 Completed Series A funding (KRW 22.4 billion total, including KRW 13 billion from Ildong Pharmaceuticals)
-
- 08 Phase 1 IND for Ildong Pharmaceutical FXR agonist approved by the US FDA
11 Patent application filed for CDK Inhibitor
-
- 02 Patent application filed for CXCR7 agonist
03 Patent application filed for SOS1 inhibitor
